Digital Healthcare
source: by Timothy Hay When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes. But it was more of […]
Read More
Our portfolio company Assurex Health just announced the creation of a partnership with Canada’s Center for Addiction and Mental Health (CAMH), one of the world’s leading research centers in the area of addiction and mental health and Canada’s largest mental health teaching hospital. CAMH will offer to Canadian citizens the firm’s pharmacogenomic test, GeneSight, which […]
Read More
Our portfolio company NuMedii just announced a groundbreaking collaboration with Thomson Reuters, the world’s leading information provider for businesses. The Thomson Reuters Science division has quietly been aggregating an enormous database of biological, clinical, and pharmacological information over the past few years. As a biotech startup, NuMedii is focused on revolutionizing drug discovery by reducing […]
Read More
Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry. The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing […]
Read MoreBig Data Guru and Stanford Medical School Professor Atul Butte, co-founder of Numedii had his work recently profiled in the journal SCIENCE. As the article claims, the explosion of publicly available databases housing sequences, structures, and images allows life scientists to make fundamental discoveries without ever getting their hands “wet” at the lab bench. Science Journal calls […]
Read MoreI’m excited that we have recently added a new portfolio company Genalyte to the Claremont Creek digital healthcare family. I’ll be joining the Board, and I am looking forward to working with founder and CEO Cary Gunn and the Genalyte team. Genalyte is a developer and manufacturer of advanced biomarker detection technology strategically located right […]
Read MoreMeet our team
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.
NAT GOLDHABER
Nat Goldhaber is a co-founder of Claremont Creek Ventures.
BRAD WEBB
Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
RANDY HAWKS
Randy Hawks is a co-founder of Claremont Creek Ventures.